Viewing Study NCT06028633


Ignite Creation Date: 2025-12-25 @ 2:52 AM
Ignite Modification Date: 2025-12-28 @ 8:55 PM
Study NCT ID: NCT06028633
Status: NOT_YET_RECRUITING
Last Update Posted: 2023-09-13
First Post: 2023-08-22
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
Sponsor: Peking University First Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module